Pigache 1973.
Methods | Allocation: randomly assigned, pairs matched on clinical status and IQ, cross‐over design. Blinding: double, independent pharmacist, sealed in individual envelopes. Duration: 55 weeks (preceded by 3 months stabilisation on chlorpromazine). | |
Participants | Diagnosis: schizophrenia. N=20. Age: 30‐50 yrs. Sex: all males. History: chronic> 2 yrs, unmarried. Excluded: given ECT or Insulin therapy during the last 12 months, physically unwell. Setting: hospital. | |
Interventions | 1. Chlorpromazine cessation: placebo. N=10.
2. Chlorpromazine continuation: dose 50‐100 mg/day. N=10. Minor analgesics, antibiotics (as necessary). |
|
Outcomes | Relapse.
Mental state: BPRS, PAT.
Leaving the study early (cross over design: 2 patients; placebo at the time of leaving. 1 patient; CPZ 50% at the time of leaving). Unable to use ‐ Biochemistry: Blood + urine tests (no data). Global state: Average Global Rating Scale (no SD). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |